97 related articles for article (PubMed ID: 3197062)
1. [Non-adjuvant chemotherapy of bladder neoplasms stage T3-4 using NO-x and MO. Preliminary results of the urogenital study group of the European Organization for Research and Treatment of Cancer].
Bollack C; Jacqmin D; Splinter TA; De Pauw M
Cas Lek Cesk; 1988 Aug; 127(35):1098-100. PubMed ID: 3197062
[No Abstract] [Full Text] [Related]
2. Preoperative chemotherapy in T3-T4 Nx Mo bladder cancer with cisplatinum and methotrexate.
Denis L; Da Silva FC; Hendrickx L
Prog Clin Biol Res; 1988; 260():571-7. PubMed ID: 3362906
[No Abstract] [Full Text] [Related]
3. Systemic chemotherapy in the management of advanced bladder cancer.
Hall RR
Arch Esp Urol; 1990; 43 Suppl 2():193-6. PubMed ID: 2096778
[No Abstract] [Full Text] [Related]
4. Neoadjuvant treatment for invasive bladder cancer: is it worthwhile?
Hall RR
Acta Urol Belg; 1996 May; 64(2):39-42. PubMed ID: 8701809
[No Abstract] [Full Text] [Related]
5. Treatment of high-stage bladder cancer: case for adjunctive chemotherapy.
Walther PJ
Semin Urol; 1993 May; 11(2):69-73. PubMed ID: 8362122
[No Abstract] [Full Text] [Related]
6. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group.
Bono AV; Benvenuti C; Reali L; Pozzi E; Gibba A; Cosciani-Cunico S; Comuzzi U; Anselmo G
Prog Clin Biol Res; 1989; 303():533-40. PubMed ID: 2675010
[No Abstract] [Full Text] [Related]
7. The evolution of active chemotherapy in metastatic and locally advanced bladder cancer.
Newling DW
Prog Clin Biol Res; 1990; 350():115-27. PubMed ID: 2201038
[No Abstract] [Full Text] [Related]
8. The cisplatin-methotrexate neo-adjuvant protocol as first-line therapy of bladder cancer. Present experience in Palermo.
Ingargiola GB; Lamartina M; Cassata G; Corselli G; Serretta V; Caramia G; Rizzo FP; Pavone-Maculuso M
Prog Clin Biol Res; 1988; 260():579-83. PubMed ID: 3362907
[No Abstract] [Full Text] [Related]
9. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
10. [Systemic chemotherapy in advanced bladder cancer. New aspects].
Jakse G
Wien Klin Wochenschr; 1987 Jan; 99(2):54-7. PubMed ID: 3564487
[TBL] [Abstract][Full Text] [Related]
11. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy in T3-4 N0-X M0 transitional cell carcinoma of the bladder. Problems of clinical and pathological evaluation of response.
Splinter TA; ten Kate FJ; Schröder FH; Denis L; Newling D; Jones WG; Jacqmin D; Boeken Kruger CG; Stoter G; de Voogt HJ
Prog Clin Biol Res; 1988; 269():579-90. PubMed ID: 3393555
[No Abstract] [Full Text] [Related]
13. Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Bosl G; Watson RC; Hollander PS
Prog Clin Biol Res; 1988; 260():551-5. PubMed ID: 3283770
[No Abstract] [Full Text] [Related]
14. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
15. [Value of adjuvant chemotherapy in infiltrating tumors of the bladder].
Callet B; Verges J
Ann Urol (Paris); 1986; 20(6):422-6. PubMed ID: 3566200
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy by means of reductive surgery and polychemotherapy (M-VAC) in the treatment of advanced bladder cancer. Our experience in 10 cases.
Valente R; Marini F; Signori GB
Prog Clin Biol Res; 1988; 260():557-9. PubMed ID: 3362904
[No Abstract] [Full Text] [Related]
17. TUR and chemotherapy or radiotherapy for invasive bladder cancer.
Hall RR; Roberts T; Powell PH; Marsh MM
Prog Clin Biol Res; 1988; 260():605-12. PubMed ID: 3129740
[No Abstract] [Full Text] [Related]
18. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
[TBL] [Abstract][Full Text] [Related]
19. [Systemic cisplatin-based chemotherapy in the treatment of advanced bladder cancer].
Boccon-Gibod L; Guinet F; Cressey-Kanoui C; Debré B; Steg A
Ann Urol (Paris); 1985; 19(4):239-43. PubMed ID: 4040730
[TBL] [Abstract][Full Text] [Related]
20. Resume of selected studies of the National Bladder Cancer Collaborative Group A and new protocols.
Prout GR; Kopp J
Prog Clin Biol Res; 1984; 162B():397-427. PubMed ID: 6438644
[No Abstract] [Full Text] [Related]
[Next] [New Search]
